Navigation Links
The Ensign Group to Present at the Stifel Nicolaus 2010 Healthcare Conference
Date:9/9/2010

MISSION VIEJO, Calif., Sept. 9 /PRNewswire/ -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, hospice care and assisted living companies, announced today that it will participate in the Stifel Nicolaus 2010 Healthcare Conference to be held on September 15-17, 2010 in Boston, Massachusetts.

(Logo:  http://photos.prnewswire.com/prnh/20071213/LATH168LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO)

Christopher R. Christensen, Chief Executive Officer, and Suzanne D. Snapper, Chief Financial Officer, will discuss the company's operations, growth strategy and related information on Wednesday, September 15, 2010 at 11:40 a.m. Pacific Time.

A live audio webcast of the company's presentation will be accessible at http://www.veracast.com/webcasts/stifel/healthcare2010/79112335.cfm. An audio recording of the webcast will be available at the same URL until October 14, 2010.

About Ensign

The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and assisted living services, physical, occupational and speech therapies, home health and hospice services, and other rehabilitative and healthcare services for both long-term residents and short-stay rehabilitation patients at 81 facilities, two hospice companies and a home health business in California, Arizona, Texas, Washington, Utah, Idaho and Colorado. More information about Ensign is available at http://www.ensigngroup.net.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This presentation and webcast may contain forward-looking statements that are based on management's current expectations, assumptions and beliefs about its business, financial performance, operating results, the industry in which it operates and other future events. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," similar expressions, and variations or negatives of these words. These forward-looking statements include, but are not limited to, statements regarding growth prospects, future operating and financial performance. They are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to materially and adversely differ from those expressed in any forward-looking statement.

These risks and uncertainties relate to the company's business, its industry and its common stock and include: reduced prices and reimbursement rates for its services; its ability to acquire, develop, manage or improve facilities, its ability to manage its increasing borrowing costs as it incurs additional indebtedness to fund the acquisition and development of facilities; its ability to access capital on a cost-effective basis to continue to successfully implement its growth strategy; its operating margins and profitability could suffer if it is unable to grow and manage effectively its increasing number of facilities; competition from other companies in the acquisition, development and operation of facilities; and the application of existing or proposed government regulations, or the adoption of new laws and regulations, that could limit its business operations, require it to incur significant expenditures or limit its ability to relocate its facilities if necessary. Readers should not place undue reliance on any forward-looking statements and are encouraged to review the company's periodic filings with the Securities and Exchange Commission, including its recently filed Form 10-K and Form 10-Q for a more complete discussion of the risks and other factors that could affect Ensign's business, prospects and any forward-looking statements. Except as required by the federal securities laws, Ensign does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changing circumstances or any other reason after the date of this press release.


'/>"/>
SOURCE The Ensign Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
3. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
4. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
5. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
6. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
7. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
8. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
11. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -- The global flow cytometry market ... 2025, according to a new study by Grand View ... cancer is expected to upsurge the demand for flow ... years. In addition, higher number of physicians is inclined ... therapy, due to adverse effects caused by chemotherapy & ...
(Date:3/27/2017)... 2017 Summary This report ... and its partnering interests and activities since 2010. Description ... in-depth insight into the partnering activity of one of the ... reports are prepared upon purchase to ensure inclusion of the ... The report will be delivered in PDF format within 1 ...
(Date:3/27/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology ... toxicology and efficacy studies. The company is harnessing the ... protein, MAGE A, in an effort to find a ... After 4 weeks of treatment in transgenic mice, ... toxicity in a full toxicology report of various organs. ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) is pleased ... new executive director. Mr. Still was selected through a careful months-long search by the ... is known to our members, has been a part of building the RBMA since ...
(Date:3/28/2017)... ... 28, 2017 , ... Award-winning medical group Allied Anesthesia today ... board chair for Orange County health care system CalOptima Friday. CalOptima announced its ... chair Mark Refowitz’s term, which runs through June 30 of this year, until ...
(Date:3/28/2017)... Lithuania (PRWEB) , ... March 28, 2017 , ... ... technologies, today announced the release of two biometric time and attendance tracking products: ... Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition to ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER TOLEDO Process Analytics is ... plant water and steam. , Chlorides and sulfates cause pitting and stress corrosion ... maintenance and unplanned shutdowns. Monitoring these ions at low ppb levels has therefore ...
(Date:3/28/2017)... ... ... The Executives, Staff & Clients of MGE: Management Experts joined forces with ... Campaign at their Semi-Annual Graduation and Fundraiser Event at MGE’s St. Petersburg Office. , ... 14 internationally in literacy. Statistically, a direct relation can be a found between illiteracy ...
Breaking Medicine News(10 mins):